Roche sees Dx unit outperform market, but hit by strong Swiss franc
This article was originally published in Clinica
Executive Summary
Roche's diagnostics division looks to be holding strong as the group's nine-month financial results revealed that the unit's top-line continues to grow faster than the global IVD market.